Amid turmoil, Elan chief turns down bonus

Nothing like a big management fight to make a CEO feel guilty about taking a bonus. Elan chief Kelly Martin turned down his 2008 incentive cash, which cut his earnings for the year to $830,000. Last year, Martin also waived his cash bonus, but he took options instead. In total, his 2007 compensation came in at $1.9 million. So his 2008 pay was less than half of 2007's.

In Elan's annual report, Martin said 2008 had been a year of "rigorous self-evaluation." No kidding. Management has been under fire for everything from their frequent use of the corporate jet to their alleged mismanagement of the company's lead drug, the MS treatment Tysabri.

Currently, Elan is in the midst of a Citigroup-advised look at its strategic options, which could end in the sale of a minority stake in the firm. As you know, folks have even speculated that the entire company could be up for grabs, and Denmark's Lundbeck was said to be in the hunt. In the meantime, Elan has been cutting jobs; 115 got the axe in Ireland and another 115 were slashed in the U.S.

- see Elan's press release
- read the story at RTÉ Business
- get the news from the Irish Independent

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.